Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SZSE:002399.SZ
11.65 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 5,280.713 | 5,445.572 | 7,159.411 | 6,365.177 | 5,332.075 | 4,624.654 | 4,814.965 | 2,670.206 | 2,260.932 | 2,292.3 | 1,958.861 | 1,513.169 | 1,761.82 | 2,494.581 | 3,853.448 | 2,224.124 | 435.221 | 299.382 | 277.795 |
| Cost of Revenue
| 3,524.558 | 3,645.269 | 4,825.01 | 4,332.138 | 3,244.269 | 2,899.176 | 2,884.718 | 2,030.197 | 1,537.596 | 1,443.572 | 1,393.487 | 1,136.965 | 1,094.442 | 1,774.538 | 2,231.671 | 1,150.47 | 190.822 | 195.26 | 192.048 |
| Gross Profit
| 1,756.155 | 1,800.303 | 2,334.401 | 2,033.039 | 2,087.806 | 1,725.478 | 1,930.247 | 640.009 | 723.336 | 848.728 | 565.374 | 376.204 | 667.378 | 720.043 | 1,621.777 | 1,073.654 | 244.399 | 104.122 | 85.747 |
| Gross Profit Ratio
| 0.333 | 0.331 | 0.326 | 0.319 | 0.392 | 0.373 | 0.401 | 0.24 | 0.32 | 0.37 | 0.289 | 0.249 | 0.379 | 0.289 | 0.421 | 0.483 | 0.562 | 0.348 | 0.309 |
| Reseach & Development Expenses
| 203.695 | 184.663 | 252.142 | 221.099 | 160.008 | 148.714 | 186.853 | 79.63 | 62.045 | 97.173 | 59.458 | 39.972 | 30.088 | 25.525 | 158.556 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 145.315 | 144.644 | 146.494 | 142.341 | 150.766 | 128.329 | 125.992 | 119.148 | 136.739 | 112.779 | 127.29 | 56.311 | 33.581 | 40.881 | 35.603 | 94.169 | 36.166 | 17.283 | 22.898 |
| Selling & Marketing Expenses
| 309.359 | 445.486 | 518.502 | 430.493 | 408.901 | 411.32 | 290.273 | 63.582 | 42.172 | 23.067 | 13.034 | 5.881 | 4.474 | 4.955 | 3.707 | 3.696 | 2.327 | 2.021 | 2.009 |
| SG&A
| 454.675 | 590.13 | 664.996 | 572.835 | 559.667 | 539.649 | 416.265 | 182.73 | 178.911 | 135.846 | 140.325 | 62.192 | 38.054 | 45.837 | 39.31 | 97.866 | 38.492 | 19.304 | 24.907 |
| Other Expenses
| 348.134 | 1,888.651 | 294.714 | 274.94 | 241.301 | 208.136 | 9.7 | 11.906 | 40.005 | 47.221 | 7.001 | 4.575 | 1.713 | 1.27 | 0.337 | 2.02 | 0.37 | 0.36 | -0.01 |
| Operating Expenses
| 1,014.844 | 2,661.214 | 1,211.852 | 1,068.874 | 960.975 | 896.499 | 845.393 | 450.609 | 457.109 | 398.715 | 324.28 | 224.77 | 175.991 | 148.713 | 229.92 | 98.889 | 38.794 | 19.691 | 25.112 |
| Operating Income
| 741.311 | -259.948 | 1,135.136 | 773.203 | 1,329.956 | 1,314.734 | 721.148 | -7.402 | 435.611 | 643.896 | 390.182 | 375.258 | 727.006 | 719.572 | 1,416.626 | 959.766 | 197.895 | 73.19 | 51.94 |
| Operating Income Ratio
| 0.14 | -0.048 | 0.159 | 0.121 | 0.249 | 0.284 | 0.15 | -0.003 | 0.193 | 0.281 | 0.199 | 0.248 | 0.413 | 0.288 | 0.368 | 0.432 | 0.455 | 0.244 | 0.187 |
| Total Other Income Expenses Net
| -15.082 | -220.435 | -305.285 | -430.613 | -233.123 | 568.005 | -263.316 | 11.96 | 39.328 | 275.642 | 173.921 | 230.566 | 239.526 | 148.711 | 26.746 | -12.979 | -0.482 | 0.36 | -0.01 |
| Income Before Tax
| 726.229 | -480.383 | 829.851 | 222.263 | 1,327.836 | 1,314.936 | 730.848 | 4.505 | 474.939 | 690.542 | 396.61 | 378.983 | 728.483 | 720.019 | 1,416.913 | 961.786 | 197.412 | 73.55 | 51.93 |
| Income Before Tax Ratio
| 0.138 | -0.088 | 0.116 | 0.035 | 0.249 | 0.284 | 0.152 | 0.002 | 0.21 | 0.301 | 0.202 | 0.25 | 0.413 | 0.289 | 0.368 | 0.432 | 0.454 | 0.246 | 0.187 |
| Income Tax Expense
| 101.311 | -126.175 | 115.164 | -11.12 | 306.204 | 271.382 | 138.664 | -113.684 | 88.821 | 122.464 | 61.278 | 65.563 | 111.932 | 101.081 | 208.118 | 152.729 | 36.019 | 5.389 | 4.046 |
| Net Income
| 646.742 | -783.258 | 727.426 | 240.788 | 1,024.21 | 1,059.356 | 616.194 | 131.33 | 396.892 | 579.777 | 338.278 | 317.335 | 624.393 | 622.083 | 1,209.503 | 809.057 | 161.393 | 68.161 | 47.884 |
| Net Income Ratio
| 0.122 | -0.144 | 0.102 | 0.038 | 0.192 | 0.229 | 0.128 | 0.049 | 0.176 | 0.253 | 0.173 | 0.21 | 0.354 | 0.249 | 0.314 | 0.364 | 0.371 | 0.228 | 0.172 |
| EPS
| 0.44 | -0.53 | 0.5 | 0.16 | 0.76 | 0.85 | 0.49 | 0.16 | 0.32 | 0.46 | 0.26 | 0.25 | 0.49 | 0.49 | 1.96 | 0.7 | 0.56 | 0.24 | 0.17 |
| EPS Diluted
| 0.44 | -0.53 | 0.5 | 0.16 | 0.76 | 0.85 | 0.49 | 0.16 | 0.32 | 0.46 | 0.26 | 0.25 | 0.49 | 0.49 | 1.96 | 0.7 | 0.56 | 0.24 | 0.17 |
| EBITDA
| 1,198.465 | 124.72 | 1,372.752 | 867.674 | 1,677.884 | 1,834.447 | 1,124.679 | 348.641 | 757.944 | 891.087 | 468.916 | 404.78 | 507.968 | 732.369 | 1,433.149 | 981.773 | 211.516 | 89.574 | 60.635 |
| EBITDA Ratio
| 0.227 | 0.023 | 0.192 | 0.136 | 0.315 | 0.397 | 0.234 | 0.131 | 0.335 | 0.389 | 0.239 | 0.268 | 0.288 | 0.294 | 0.372 | 0.441 | 0.486 | 0.299 | 0.218 |